23,24 Furthermore, DDR inhibitors, such as ATR and CHK1 inhibitors, have emerged as therapeutic agents for individuals with lesions in DDR genes, and clinical trials are ongoing.25 Hence, suboptimal detection of germline variants in HRD and DDR genes could significantly hinder therapeutic efforts in cancer patients. This evidence concerns the gene CHEK1 and cancer.